Incidence and prevalence of dementia in linked administrative health data in Saskatchewan, Canada : a retrospective cohort study by Kosteniuk, JG et al.
RESEARCH ARTICLE Open Access
Incidence and prevalence of dementia in linked
administrative health data in Saskatchewan,
Canada: a retrospective cohort study
Julie G. Kosteniuk1*, Debra G. Morgan2, Megan E. O’Connell3, Andrew Kirk4, Margaret Crossley5, Gary F. Teare6,
Norma J. Stewart7, Vanina Dal Bello-Haas8, Dorothy A. Forbes9, Anthea Innes10 and Jacqueline M. Quail6
Abstract
Background: Determining the epidemiology of dementia among the population as a whole in specific jurisdictions –
including the long-term care population–is essential to providing appropriate care. The objectives of this study
were to use linked administrative databases in the province of Saskatchewan to determine the 12-month incidence
and prevalence of dementia for the 2012/13 period (1) among individuals aged 45 and older in the province of
Saskatchewan, (2) according to age group and sex, and (3) according to diagnosis code and other case definition
criteria.
Methods: We used a population-based retrospective cohort study design and extracted data from 10 provincial
health databases linked by a unique health services number. The cohort included individuals 45 years and older at
first identification of dementia between April 1, 2001 and March 31, 2013 based on case definitions met within any
one of four administrative health databases (Hospital Discharge Abstracts, Physician Service Claims, Prescription Drug,
and RAI-MDS, i.e., Long-term Care).
Results: A total of 3,270 incident cases of dementia (7.28 per 1,000 PAR) and 13,012 prevalent cases (28.16 per
1,000 PAR) were identified during 2012/13. This study found the incidence rate increased by 2.8 to 5.1 times
and the prevalence rate increased by 2.6 to 4.6 times every 10 years after 45 years of age. Overall, the
age-standardised incidence rate was significantly lower among females than males (7.04 vs. 7.65 per 1,000 PAR)
and the age-standardised prevalence rate was significantly higher among females than males (28.92 vs. 26.53
per 1,000 PAR). Over one-quarter (28 %) of all incident cases were admitted to long-term care before a diagnosis was
formally recorded in physician or hospital data, and nearly two-thirds of these cases were identified at admission with
impairment at the moderate to very severe level or a disease category of Alzheimer’s disease/other dementia.
Conclusions: Linking multiple sources of registry data contributes to our understanding of the epidemiology of
dementia across multiple segments of the population, inclusive of individuals residing in long-term care. This
information is foundational for public awareness and policy recommendations, health promotion and prevention
strategies, appropriate health resource planning, and research priorities.
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Background
Worldwide, it is estimated that there is one incident
case of dementia every 4 seconds, or 7.7 million inci-
dent cases each year [1]. The most recent estimates show
that 44 million people now live with dementia, which is
projected to increase to 135 million by 2050 [2]. Historic-
ally low fertility rates and improved life expectancy are
expected to be the main drivers of population aging [3],
with the absolute number of older adults aged 65 years
and older tripling worldwide from 524 million in 2010 to
1.5 billion in 2050 [4]. Among individuals aged 60 years
and over in 2010, dementia prevalence was between 5-7 %
worldwide; dementia onset before the age of 65 (i.e., early
onset dementia) was estimated to account for 6-9 % of all
prevalent cases [2]. International recognition of the asso-
ciation between population aging and the growing num-
bers of individuals with chronic and degenerative diseases
has resulted in greater attention on dementia as a signifi-
cant global health challenge [2].
As a result of the first-ever G8 dementia summit held
in 2013, a new Global Envoy for Dementia Innovation
was appointed and an agreement was reached to collab-
orate internationally on dementia research that included
an investment in ‘making timely diagnosis and early
intervention feasible, affordable and cost effective’ as one
of five priorities [5]. Many national dementia plans pro-
pose initiatives to improve detection and formal diag-
nosis. The more prominent of these initiatives involve
building capacity among health care professionals to
diagnose and treat dementia in its early stages, improv-
ing public awareness of symptoms and stigma associated
with resistance to help-seeking, and improving the avail-
ability and accessibility of diagnostic and post-diagnosis
resources [6–8].
Three separate systematic reviews have found that
between 31 % and 69 % of patients with dementia in
primary care do not receive a formal, i.e., documented
diagnosis; formal diagnosis is less likely to occur among
mild than moderate or severe cases [9–11]. Sternberg and
colleagues [12] found that two of every three community-
dwelling Canadian seniors (64 %) with dementia were
undetected, defined as “never having seen a physician for
memory problems”. Key factors that have been identified
as possible barriers to formal diagnosis include patient
and caregiver issues such as lack of symptom awareness,
lack of support to seek help, and attitudes such as re-
sistance to receiving a diagnosis and perceived stigma;
health care professional attitudes such as poor knowledge
and adherence to clinical practice guidelines, diagnostic
uncertainty and difficulties in diagnosis disclosure, and
skepticism regarding the effectiveness of treatment (i.e.,
therapeutic nihilism [13]); and health system factors such
as limited time to conduct consultations and poor access
to diagnostic information and resources [10, 11, 14].
An essential step in providing appropriate care for
people with dementia is ascertaining the burden of the
disease among the population as a whole – including the
long-term care population – in specific jurisdictions.
Findings from field studies (i.e., two-phase studies with
screening followed by a structured clinical evaluation)
contribute to current evidence in this regard. However,
field studies of dementia epidemiology typically do not
combine community-dwelling and institutionalized pop-
ulations e.g., [15–18], including one of the most com-
prehensive reports of global dementia epidemiology [1].
Some field studies have combined these populations
e.g., [19, 20]. Registry studies (i.e., based on adminis-
trative health data), such as the current study, are useful
for several reasons, foremost being the information upon
which to base policy recommendations, public awareness
activities, health promotion and prevention strategies,
health resource planning, and research priorities. The cu-
rrent study included a lower age cut-off of 45 years in
order to identify the incidence and prevalence of ‘early
onset dementia’, that is dementia in individuals younger
than age 65 years. This information is useful for planning
the health and social care services necessary to address
the unique needs of individuals with early onset dementia
and their families [21]. In addition to providing critical
policy information, the current study includes a compa-
rison of specific diagnosis codes and other criteria used
in our case definition with other similar recent studies,
and as such offers: (1) increased awareness of the nature
and availability of codes to record disease diagnoses;
(2) improved understanding of the role of diagnosis codes
in estimating disease incidence and prevalence; (3) oppor-
tunity for transparency in the development of definitions
to identify cases and potential for common agreement
among researchers on such definitions; and (4) compari-
sons of rates and risk factors among regions with access
to similar data [22, 23]. The objectives of the present
study were to use linked administrative databases in the
province of Saskatchewan to determine the 12-month
incidence and prevalence of dementia (1) among individ-
uals aged 45 and older in the province of Saskatchewan,
(2) according to age group and sex, and (3) according to
diagnosis code and other case definition criteria.
Methods
Setting
The province of Saskatchewan (Canada) covers 651,000 km2
and has a population of over 1.08 million [24]. In 2012,
two cities in the province each had populations over
100,000 (census metropolitan areas [CMAs]) that together
accounted for 46.6 % of the population [25]; communities
and areas outside of these CMAs contributed 53.4 % of
the population. Individuals aged 0 to 14 years accounted
for 18.8 % (204,436), those 15 to 44 years of age made up
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40.4 % (439,041), individuals 45 to 64 years of age
accounted for 26.4 % (287,286), and those aged 65 years
and older made up 14.4 % (156,873) of the population
[24]. The median age of the provincial population was
37.1 years in 2012 [26].
In Canada’s publicly funded system of universal health
care, each of Canada’s 10 provinces and 3 territories is
responsible for the provision of ‘medically necessary
hospital and physician services’ to its citizens [27]. De-
termination of the services that are medically necessary,
i.e., fully covered services, is the separate responsibility
of each province and territory. In Saskatchewan, many
services beyond inpatient and outpatient care provided
by physicians are fully covered, including immunizations
for children, physiotherapy in hospitals and special care
homes, and mental health services [28]. All residents of
Saskatchewan are eligible for health insurance to receive
fully covered services with the exception of those cov-
ered by federal health insurance (e.g., federal prison
inmates, members of the Canadian Forces and Royal
Canadian Mounted Police) and individuals who do not
meet the residency requirements of Saskatchewan (i.e.,
those who have lived in the province for a period of less
than three months or have moved elsewhere for a period
of more than three months) [29]. In addition, the Pre-
scription Drug Plan excludes the Registered Indian po-
pulation and other residents whose costs are covered by
another government body [30]. Saskatchewan residents
who receive health insurance benefits comprise the ‘cov-
ered population’.
Data sources
This analysis used data extracted from 10 provincial
health databases linked by a unique personal health ser-
vices number assigned to individuals eligible for health
insurance benefits [30]. Home Care data were not avail-
able for analysis. The databases were accessed, linked,
and analysed by researchers at the Saskatchewan Health
Quality Council (HQC) through a formal data sharing
agreement between HQC and the Saskatchewan Minis-
try of Health.
The Hospital Discharge Abstract Database includes
patient information, most responsible diagnosis for hos-
pitalization, other diagnoses, principal procedure, other
procedures, accident code, and hospital discharge dates.
Prior to April 1, 2002, four-digit ICD-9 codes were used
to record a maximum of 16 diagnoses per record. Five-
digit ICD-10-CA codes were introduced April 1, 2001,
after which time approximately 30 % of hospitals in
Saskatchewan continued to use ICD-9 codes. By April 1,
2002, the transition to ICD-10-CA codes was complete
and all hospitals were using this 5-digit coding system to
record up to 25 diagnoses per record.
The Physician Services Claims Database includes in-
formation used by physicians to claim payment from the
provincial government for services provided to patients.
Patient information is included, as well as service in-
formation such as date, fee code, type, diagnosis code
associated with service (maximum of one diagnosis code
per service claim), location, and payment information
[30]. Physicians who are remunerated on a non-fee-for-
service basis are also expected to submit similar ‘shadow’
or ‘dummy’ billing claims. Although approximately 16 %
of full-time equivalent physicians receive payment on a
non-fee-for-service basis, the completeness of the shadow
billing claims is unknown [31]. The Physician Mobility
File contains physicians’ identification numbers and spe-
cialties. More than 70 specialty categories based on phys-
ician certification are available [31].
The two Prescription Drug Databases (ALLDIN and
Historical Claims) include information regarding the
dispensing pharmacy as well as information about the
drug dispensed such as classification of drug, drug identi-
fication number (DIN), type and class, generic and brand
names, strength and dosage, date and quantity dispensed,
and cost. Only those drugs listed in the Saskatchewan For-
mulary are eligible for coverage under the Saskatchewan
Drug Plan. The prescription costs for the Registered
Indian population are paid by the federal government and
therefore prescriptions for these individuals are not in-
cluded in the Prescription Drug Database [30]. The Regis-
tered Indian population accounted for approximately 13 %
of the Saskatchewan population in 2012 [32].
The Resident Assessment Instrument – Minimum Data
Set (RAI-MDS), (i.e., Long-term Care Database), contains
information gathered from the assessment of individuals
at the time of admission to a residential care facility and
at regular three-month intervals [33]. Residents also
receive an assessment if their clinical status changes
significantly. Included in the data are: residents’ identifi-
cation and background information, disease diagnoses,
health conditions, skin condition, medication list, as well
as measures of mood and behaviour, vision, cognition,
communication and hearing, accidents, physical function-
ing, clinical management, continence, oral and nutrition
status, activity patterns, and psychosocial well-being. Ad-
mission and quarterly assessment data were included in
the present study. These data have been used extensively
for research and their validity for use in research has been
confirmed in multiple studies [34–36].
The Institutional Supportive Care Data Set contains in-
formation on the facilities that house long-term residents.
The Person Health Registration System, Saskatchewan
Resident Geography, and Vital Statistics databases contain
information regarding status and dates of insurance
coverage, gender, dates of birth and death, urban vs. rural
residence, and health region of residence.
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Cohort
Selection of case definition criteria
A three-stage process was used to develop the case
definition algorithm. The first stage consisted of conduct-
ing an overview of recent Canadian studies that employed
administrative data to determine the dementia incidence
or prevalence in the general population, to identify previ-
ous criteria used to define cases of dementia (see Table 1
and Additional file 1). Canadian studies were chosen for
comparison due to the similarity of features among
administrative databases across the country, specifically
the availability of physician services databases in 11 of 13
provinces, the similar duration of data availability, and
the use of similar diagnosis and procedure codes across
provinces [31]. The second stage involved separate re-
views of the case definition criteria employed in the
selected Canadian studies by: (1) the Rural and Remote
Memory Clinic team consisting of the director (DM),
neurologist (AK) and neuropsychologists (MC and MO),
and (2) a Steering Committee that included family phy-
sicians, nurse practitioners, as well as leadership from the
Alzheimer Society of Saskatchewan and health regions.
The final stage consisted of consolidating the reviews and
reaching consensus among the clinical team members on
the diagnosis codes and other criteria that comprised the
case definition algorithm.
Case definition criteria
The cohort included individuals aged 45 years and older
at their first-ever recorded identification of dementia
(i.e., index date) between April 1, 2001 and March 31,
2013 in one of four administrative health databases
(Hospital Discharge Abstracts, Physician Service Claims,
Prescription Drug, and RAI-MDS, i.e., Long-term Care).
Eligible individuals had continuous health insurance co-
verage from the start of their insurance until one of the
following: March 31, 2013, the expiration of their insur-
ance, or their death. Individuals with gaps of no more
than 3 consecutive days in their coverage were consid-
ered to have continuous health insurance. The case defin-
ition algorithm employed in the present study is provided
in Table 1 and the identification of the study cohort is
shown in Fig. 1. The specific criteria applied to the four
administrative health databases were as follows:
1. Hospital Discharge Abstracts (ICD-10-CA codes:
F00, F01, F02, F03, F04, F05.1, F06.8, F06.9, F09,
F10.6, F10.7, F18.6, F18.7, F19.6, F19.7, G30, G31.0,
G31.1, G91, R54);
2. Physician Services Claims (ICD-9 codes: 290, 294,
331, 797);
3. Prescription Drug (Aricept DINs: 02232043,
02232044; Exelon DINs: 02242115–02242118,
02245240; Reminyl DINs: 02244298–02244300,
02266717, 02266725, 02266733);
4. Long-term Care, i.e., RAI-MDS (Cognitive Perform-
ance Scale (CPS) score of 2 and over, indicating mild
to very severe impairment) [37]
and/or a disease category of Alzheimer’s disease
or dementia other than Alzheimer’s disease.
If individuals had the same index date in two or
more databases, they were identified first in the phys-
ician database, then in the hospital, then RAI-MDS,
and lastly the drug database. If individuals had a CPS
score of 2 or over recorded on the same index date as
a disease category of Alzheimer’s disease and/or demen-
tia other than Alzheimer’s disease, they were identified
first by the CPS score, then by the disease category of
Table 1 Case definition algorithms employed to identify dementia in administrative health databases, by Canadian study
Study/Institute Case definition algorithmb Age group Timeframe
Present studya ≥1 physician visits or ≥ 1 hospitalizations or ≥ 1 prescriptions
for a cholinesterase inhibitor or [a RAI-MDS CPS score of≥ 2
and/or (a disease category of Alzheimer’s disease or dementia
other than Alzheimer’s disease)]
≥45 years 1 year (2012–2013)
Manitoba Centre for
Health Policy [38]c
≥1 physician visits or ≥ 1 hospitalizations ≥55 years Not applicableb
Chartier et al. [39] ≥1 physician visits or ≥ 1 hospitalizations ≥55 years 5 years (2004–2009)
Martens et al. [40] ≥1 physician visits or ≥ 1 hospitalizations ≥55 years 5 years (2002–2007)
Fransoo et al. [41] ≥1 physician visits or ≥ 1 hospitalizations ≥55 years 5 years (1996–2001) and 5 years (2001–2006)
Gill et al. [42] ≥1 physician visits or ≥ 1 hospitalizations or any
cholinesterase inhibitor prescription
66-105 years 5 years (2002–2007) for physician and hospital
data; 1 year for prescription data (2006–2007)
Jacklin et al. [43] ≥1 physician visits all ages 1 year (2008–2009)
Jacklin and Walker [44] ≥2 physician visits or ≥ 1 hospitalizations ≥60 years 1 year (2006–2007)
aSee ‘Case definition criteria’ for the complete case definition algorithm employed in the present study
bSee Additional file 1 for the diagnosis codes and other criteria employed to identify dementia cases in the studies
cResearch institute
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Alzheimer’s disease, and last by the disease category of
dementia other than Alzheimer’s disease.
As shown in Table 1, all of the previous studies that
employed administrative data to define dementia used
physician data, and most often, also used hospital data
[38–44]. The case definitions used in the majority of
these studies required a minimum of one physician visit
or one hospitalization. Also, the lower age cut-offs varied
from no cut-off (i.e., all ages included) to 66 years.
Diagnosis codes and other criteria employed in the
case definition algorithm for the present study were
selected with a goal to achieve sensitivity over specifi-
city, given substantial evidence that dementia underdi-
agnosis is a significant and global phenomenon [7, 9, 45].
Certain neurologic conditions, such as Alzheimer’s dis-
ease and Parkinson’s disease, do not have a diagnostic
test for confirmation purposes and it may be more chal-
lenging for physicians to assign a diagnosis code to these
conditions compared to other neurologic conditions [46].
A recent systematic review of studies that validated the
use of specific ICD-9 and ICD-10 codes in administrative
health data found eight studies that tested a total of 21
case definitions of dementia against a reference standard
[46]. On average, specificity was higher than 84 % (range
of 56.3 % to 100 %), while sensitivity ranged from 8 % to
86.5 %. While case definitions of dementia that employ
numerous ICD-9 and ICD-10 diagnosis codes may be
highly sensitive to identifying people who actually have
Fig. 1 Identification of incident and prevalent cases of dementia (2012/13) based on case definition criteria
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dementia, the challenge is that individuals without de-
mentia may also be captured in these same case defini-
tions. In the present study, sensitivity was pursued by
employing a case definition algorithm that targeted indi-
viduals who may not have had a formal diagnosis in phy-
sician or hospital data, but who may have sufficiently
satisfied other criteria to be included in the dementia
cohort. These other criteria related to prescription drug
and long-term care services, and are described in the case
definition algorithm (Table 1 and Additional file 1).
Hospital data As shown in Additional file 1, the ICD-9
codes used to identify dementia cases in hospital data
during the ‘washout period’ of 1996 to 2001 (i.e., run-in
period to ensure that cases identified after April 1, 2001
were in fact incident cases, and had not been previ-
ously identified) in the present study were identical to
codes recommended by the Manitoba Centre for Health
Policy (MCHP) [38], and used by Chartier et al. [39].
Recent recommendations from MCHP exclude most
diagnosis codes that refer to the involvement of alcohol
or drugs. Therefore, the present study excluded most
ICD-9 codes with elements of alcohol or drugs that did
not also contain specific reference to a dementia (i.e.,
291.3, 291.4, 291.5, 291.8, 291.9, 292.0, 292.1, 292.2,
292.9) in contrast to earlier studies [40, 41].
Following MCHP recommendations, and in accordance
with earlier studies [40, 41], the present study included
ICD-10-CA codes of mental and behavioural disorders
due to: ‘alcohol, residual and late-onset psychotic disorder’
(F10.7), ‘volatile solvents, residual and late-onset psychotic
disorder’ (F18.7), and ‘multiple drug use and use of other
psychoactive substances, residual and late-onset psychotic
disorder’ (F19.7). In contrast to MCHP recommendations
but still in accordance with earlier studies [40, 41], the
present study included hospital ICD-10-CA codes (2001–
2013) of mental and behavioural disorders due to: ‘alcohol,
amnesic syndrome’ (F10.6), ‘volatile solvents, amnesic
syndrome’ (F18.6), and ‘multiple drug use and use of other
psychoactive substances, amnesic syndrome’ (F19.6).
Physician data The present study followed MCHP
recommendations regarding the inclusion of ICD-9 codes
in physician data (2001–2013). Diagnoses of ‘alcohol
psychoses’ (291) and ‘drug psychoses’ (292) used in earlier
studies [40, 41] were not used in the present study. The
Saskatchewan physician data contain 3-digit ICD-9
codes, and specific dementia-related diagnoses that
are specified in the 4th digit of ICD-9 that we would
otherwise have included could not be included in the
case definition (i.e., 291.1 ‘Korsakov’s psychosis’ and
291.2 ‘other alcoholic dementia’).
Prescription drug data Three cholinesterase inhibitors,
Aricept, Exelon, and Reminyl, were included in the case
definition algorithm for the present study. Aricept (done-
pezil), Reminyl (galantamine), and Exelon (rivastigmine)
are the only three cholinesterase inhibitors currently pre-
scribed in Canada [47]. Cholinesterase inhibitors are con-
sidered first-line pharmacotherapy for the purpose of
improving symptoms associated with dementia due to
Alzheimer’s disease [AD] [48]. While other medications
may be used to treat AD (e.g., memantine) [47], these
three cholinesterase inhibitors are the most common
medications used and are typically prescribed only for the
treatment of dementia.
Long-term care data Individuals whose index date was
within 30 days after their date of admission to long-term
care were considered to be identified ‘at admission’ to
account for the reality that some staff, particularly in
smaller facilities, were not able to conduct a resident’s
assessment on the same day as admission. With respect
to the use of RAI-MDS (long-term care) data in the case
definition algorithm, a Cognitive Performance Scale
score of 2 or higher was required, and/or a disease cat-
egory of Alzheimer’s disease or dementia other than Alz-
heimer’s disease. The disease categories are based on
transfer documentation, medical records, and informa-
tion provided by the patient that has been verified by a
physician [33]. A CPS score of 2 or higher is equivalent
to an average Mini Mental State Examination score of 19
or lower [49], indicating possible mild to very severe im-
pairment [37] and dementia at the moderate to severe
stage [50]. Validated against physician diagnosed demen-
tia in a sample of older hospitalized patients [51], a CPS
score of 2 or higher had moderate sensitivity (0.68) and
very good specificity (0.92). Validated against the Cam-
bridge Examination for Mental Disorders of the Elderly-
Revised (CAMDEX-R) in a sample of older nursing home
residents, a CPS score of 2 or higher had good sensitivity
(0.81) and specificity (0.80) for the detection of cognitive
impairment [52].
Measures
Three independent variables were included in the ana-
lysis: sex, age, and administrative health database. The
age groupings were 45–54, 55–64, 65–74, 75–84, and
85 years and over. Hospital, physician, prescription drug,
and long-term care represented the four administrative
health databases.
Statistical analysis
All analyses were conducted with SAS 9.3 (SAS Institute
Inc, Cary NC). The number of incident dementia cases
was calculated for each 12-month period from April 1,
2001 to March 31, 2013. Only the 12-month period of
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2012–2013 is reported in this paper. New cases of
dementia included individuals who met the case defin-
ition criteria and did not have a previous identification
of dementia during the ‘washout’ period between April
1, 1996 and March 31, 2001 in any of the following data-
bases: (1) Hospital Discharge Abstracts (ICD-9 codes:
290, 291.1, 291.2, 292.8, 294, 331, and 797); (2) Physician
Services Claims Database (ICD-9 codes: 290, 294, 331,
797); and (3) Prescription Drug (Aricept, Exelon, or
Reminyl).
The numerator for the 2012/2013 incidence rate per
1,000 population at risk (PAR) was the number of people
who were alive on April 1, 2012 and who met the case
definition of dementia between April 1, 2012 and March
31, 2013. The denominator consisted of the population
at risk of incident dementia, which included all indivi-
duals in the covered population aged 45 years or older
on April 1, 2012 with at least one day of health insu-
rance coverage for the 12-month period, after removing
individuals with prevalent dementia for the same period.
Dementia prevalence was calculated for each 12-
month period from 2002 to 2013, April 1 to March 31
inclusive. Prevalent cases of dementia included indivi-
duals who met the case definition criteria for each 12-
month period. Only data for the 2012–2013 12-month
period are presented in this paper. The numerator for
the 2012/2013 prevalence rate per 1,000 PAR was the
number of individuals who met the case definition
criteria at any time prior to April 1, 2012 and were alive
on April 1, 2012. The denominator was the number of
individuals at risk for prevalent dementia, that is, all
individuals in the covered population aged 45 years or
older on April 1, 2012 with at least one day of health
insurance coverage for the 12-month period.
Sex-specific incidence and prevalence rates were ad-
justed for age distribution using the age structure of the
total cohort. Female to male age-standardised incidence
and prevalence rate ratios (RR) were calculated by divi-
ding female rates by male rates, and 95 % confidence
intervals (CI) were calculated for all crude rates, age-
standardised rates, and rate ratios.
Ethics
This study received ethics approval from the University
of Saskatchewan Biomedical Research Ethics Board (Bio-
REB #12-339).
Results
Incidence by sex and age group
Overall, 3,270 incident cases of dementia were identified
among adults aged 45 years and older in Saskatchewan
for the 2012/13 period (Fig. 1). The majority of these
individuals (98.2 %) had continuous health insurance
coverage for five years prior to identification of dementia.
As shown in Table 2, the 12-month incidence rate
among all adults was 7.28 per 1,000 population at risk
(PAR). Adults under 65 years contributed 7.55 % of the
incident cases (247/3,270), those aged 65 to 84 contrib-
uted 41.07 % (1,343/3,270), and 51.38 % (1,680/3,270)
were contributed by adults aged 85 and older. The shar-
pest escalation in the incidence rate occurred at age 75,
increasing by 5.07 times (20.03 per 1,000 PAR) compared
to the group aged 65 to 74 (3.95 per 1,000 PAR). Among
all adults, the incidence rate increased 152 times between
the groups aged 45 to 54 and 85 years and older (0.46 vs.
69.73 per 1,000 PAR).
As shown in Table 3, a total of 1,887 incident cases in
females and 1,383 incident cases in males were observed
in adults aged 45 years and older. The number of female
and male incident cases under 75 years was similar (287
vs. 289); after age 75, female incident cases outnumbered
male cases (1,600 vs. 1,094). After adjustment for age,
the female to male standardised incidence rate ratio was
significantly different in the 85 and older age group only
(RR: 0.90, CI: 0.817-0.997, p < 0.05) (Table 4). Among all
age groups combined, the standardised incidence rate
was 8 % lower among females than males (7.04 vs. 7.65
per 1,000 PAR); the female to male rate ratio of 0.92
(95 % CI: 0.859-0.986) was significant (p < 0.05).
Prevalence by sex and age group
A total of 13,012 prevalent dementia cases among adults
aged 45 years and older in Saskatchewan were identi-
fied by administrative data analysis for the 2012/13
period (Fig. 1). Adults under 65 years contributed 8.35 %
of prevalent cases (1,087/13,012), those aged 65 to 84
accounted for 39.03 % (5,078/13,012), and adults aged
85 years and older accounted for 52.62 % (6,847/13,012).
As shown in Table 5, the prevalence rate increased stead-
ily with age, with the largest increase at 4.57 times occur-
ring between the age groups 45 to 54 and 55 to 64 (1.38
vs. 6.31 per 1,000 PAR). Overall, the prevalence rate was
160 times higher among adults aged 85 and older than
Table 2 12-month incidence of dementia among adults
45 years of age and older, Saskatchewan, by age group
(April 1, 2012 to March 31, 2013)
Age group n PAR Rate per 1,000 PAR (95 % CI)
45-54 70 153,189 0.46 (0.35-0.56)
55-64 177 137,916 1.28 (1.07-1.47)
65-74 329 83,198 3.95 (3.53-4.38)
75-84 1,014 50,616 20.03 (18.80-21.27)
85+ 1,680 24,093 69.73 (66.40-73.06)
Total 3,270 449,012 7.28 (7.03-7.53)
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among those 45 to 54 years of age (221.30 vs. 1.38 per
1,000 PAR).
There were a similar number of female and male
prevalent cases under age 75 (1,250 vs. 1,228), but a
greater number of female than male prevalent cases after
age 75 (6,849 vs. 3,685) (Table 6). Among adults aged
45 years and older, a total of 8,099 prevalent cases in
females and 4,913 prevalent cases in males were ob-
served. After adjusting for age, Table 7 shows that the
only age group for which the female to male standar-
dised prevalence rate ratio was significant was 85 and
older (RR: 1.18, 95 % CI: 1.123-1.245, p < 0.05). Among
all age groups combined, the standardised prevalence
rate was 9 % higher among females than males (28.92 vs.
26.53 per 1,000 PAR); the female to male prevalence rate
ratio was significant at 1.09 (95 % CI: 1.052-1.129, p <
0.05)
The 12-month prevalence rate was 3.9 times the 12-
month incidence rate (28.16 vs. 7.28 per 1,000 PAR),
indicating an average duration of survival from time of
identification by diagnosis or other criteria of 3.9 years.
Upon further examination, females survived an average
of 4.11 years from time of identification (28.92/7.04 per
1,000 PAR) and males survived an average of 3.47 years
(26.53/7.65 per 1,000 PAR).
Incidence and prevalence by diagnosis code and other
criteria
As shown in Table 8, the greatest proportion of all 12-
month incident cases in 2012/13 were first identified
in long-term care (34.98 %) followed closely by a diag-
nosis in physician services claims (29.94 %), and a
diagnosis in hospital (28.53 %). Of note, 6.54 % of all
incident cases were first identified as a result of a cho-
linesterase inhibitor prescription. Five separate diagno-
sis codes and other criteria represented three-quarters
of all incident cases (73.59 %): an ICD-10-CA diagno-
sis of ‘unspecified dementia’ in hospital (18.69 %), an
ICD-9 diagnosis of ‘other cerebral degenerations’ in phys-
ician services claims (14.40 %), CPS Scale scores indi-
cating mild (13.52 %) or moderate (13.49 %) impairment
in long-term care, and an ICD-9 diagnosis of ‘senile and
presenile organic psychotic conditions’ (13.49 %) in phys-
ician services claims.
Table 8 shows that prevalent cases were most likely to
be first identified by a diagnosis in physician services
claims (40.16 %). A further 24.72 % were first identified
in long-term care, 23.84 % by a diagnosis in hospital,
and 11.28 % by a cholinesterase inhibitor prescription.
Approximately 70 % of all prevalent cases were first
identified with one of five diagnosis codes and other cri-
teria: an ICD-9 diagnosis of ‘other cerebral degenerations’
in physician data (24.63 %), an ICD-10-CA diagnosis of
‘unspecified dementia’ in hospital data (13.35 %), an ICD-
9 diagnosis of ‘senile and presenile organic psychotic
conditions’ in physician data (13.13 %), and a CPS Scale
score indicating moderate (10.44 %) or mild (8.59 %)
impairment in long-term care.
As shown in Table 9, 79.72 % (912/1,144) of all inci-
dent cases that were first identified in long-term care
Table 3 12-month incidence of dementia among adults 45 years of age and older, Saskatchewan, by gender and age group
(April 1, 2012 to March 31, 2013)
Age
group
Female Male
n PAR Crude rate per
1,000 PAR (95 % CI)
Age-standardised rate
per 1,000 PAR (95 % CI)
n PAR Crude rate per
1,000 PAR (95 % CI)
Age-standardised rate per
1,000 PAR (95 % CI)
45-54 37 75,597 0.49 (0.33-0.65) 0.49 (0.33-0.65) 33 77,592 0.43 (0.28-0.57) 0.43 (0.28-0.57)
55-64 85 67,958 1.25 (0.98-1.52) 1.25 (0.99-1.52) 92 69,958 1.32 (1.05-1.58) 1.32 (1.05-1.58)
65-74 165 42,193 3.91 (3.31-4.51) 3.88 (3.29-4.47) 164 41,005 4.00 (3.39-4.61) 4.02 (3.41-4.64)
75-84 539 27,767 19.41 (17.77-21.05) 19.26 (17.63-20.88) 475 22,849 20.79 (18.92-22.66) 21.05 (19.16-22.94)
85+ 1,061 15,267 69.50 (65.31-73.68) 67.13 (63.09-71.17) 619 8,826 70.13 (64.61-75.66) 74.38 (68.52-80.24)
Total 1,887 228,782 8.25 (7.88-8.62) 7.04 (6.72-7.36) 1,383 220,230 6.28 (5.95-6.61) 7.65 (7.25-8.06)
Table 4 12-month age-standardised incidence rates and female/male rate ratios among adults 45 years of age and older,
Saskatchewan, by gender and age group (April 1, 2012 to March 31, 2013)
Age group Female age-standardised rate per 1,000 PAR Male age-standardised rate per 1,000 PAR Rate ratio SD (RR) 95 % CI
45-54 0.49 0.43 1.14 0.24 0.712-1.822
55-64 1.25 1.32 0.95 0.15 0.705-1.272
65-74 3.88 4.02 0.97 0.11 0.778-1.198
75-84 19.26 21.05 0.91 0.06 0.809-1.035
85+ 67.13 74.38 0.90 0.05 0.817-0.997
Total 7.04 7.65 0.92 0.04 0.859-0.986
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were identified at the point of admission. The remaining
20.28 % (232/1,144) were admitted to long-term care
prior to April 1, 2012 (in some cases by many years) and
were not identified as having dementia until 2012/13.
Therefore, of all incident cases, 27.89 % (912/3,270) were
first identified with dementia at admission to long-term
care. On further examination, 63.38 % (578/912) of those
first identified at the point of admission were first iden-
tified with impairment at the moderate to very severe
level (CPS Scale Score ≥ 3) or a disease category of Alz-
heimer’s disease/other dementia. The remaining 36.62 %
(334/912) of individuals first identified at the point of
admission were identified with mild impairment (CPS
Scale Score of 2). Of all prevalent cases first identified in
long-term care, 68.89 % (2,216/3,217) were identified at
admission, and 31.11 % (1,101/3,217) were identified
30 days or longer after admission. Therefore, of all pre-
valent dementia cases, 17.03 % (2,216/13,012) were first
identified with dementia at admission to long-term care.
Of those prevalent cases first identified at admission,
65.29 % (1,447/2,216) were first identified with impair-
ment at the moderate to very severe level (CPS Scale
Score ≥ 3) or a disease category of Alzheimer’s disease/
other dementia and 34.70 % (769/2,216) were identified
with mild impairment (CPS Scale Score of 2).
Discussion
In the present study, we determined the 2012/13 12-
month incidence and prevalence of dementia among
adults aged 45 years and older, as identified by a case
definition algorithm applied to linked administrative
health databases for the province of Saskatchewan (phy-
sician services claims, hospital discharge abstracts, pre-
scription drug, and long-term care).
Findings from the present study may be compared
with findings from similar registry studies as well as with
findings from field studies; however, it should be noted
that incidence and prevalence rates from registry studies
of dementia are often more comparable to one another
than to rates based on field studies. Variations in find-
ings between the present study and previous Canadian
registry studies of dementia may be due to a number of
factors. First, variations may be attributed to the use of
different case definition algorithms, i.e., the use of differ-
ent age cut-offs, as well as different periods of time and
administrative databases. A lower age cutoff, as was used
in the present study and in the study by Jacklin and
colleagues [43], results in a lower rate of prevalence.
Second, a longer observation period such as five years,
as was used in most previous Canadian registry studies
of dementia [39–42] likely results in a higher prevalence
rate than a shorter observation period such as 12 months,
as was used in the present study. Finally, employing a
greater number of databases, particularly the RAI-MDS
(LTC) database as in the present study, likely results in a
higher rate than using few databases, as in the study by
Jacklin and colleagues [43].
Incidence and prevalence
The present study determined that the overall incidence
rate of dementia among individuals aged 45 years and
older was 0.73 % (7.28 per 1,000 PAR). To the best of
our knowledge, no previous Canadian study has reported
on the incidence of dementia based on RAI-MDS (i.e.,
long-term care data) linked with physician or hospital ad-
ministrative data. In the absence of comparable Canadian
registry data, the Canadian Study of Health and Aging
[20] indicated an overall incidence rate of 20.6 per 1,000
based on a field study of community-dwelling and insti-
tutionalized Canadians aged 65 years and older. When
Table 6 12-month prevalence of dementia among adults 45 years of age and older, Saskatchewan, by gender and age group
(April 1, 2012 to March 31, 2013)
Age
group
Female Male
n PAR Crude rate per
1,000 PAR (95 % CI)
Age-standardised rate
per 1,000 PAR (95 % CI)
n PAR Crude rate per
1,000 PAR (95 % CI)
Age-standardised rate
per 1,000 PAR (95 % CI)
45-54 110 75,707 1.45 (1.18-1.72) 1.45 (1.18-1.72) 101 77,693 1.30 (1.05-1.55) 1.30 (1.05-1.56)
55-64 446 68,404 6.52 (5.91-7.13) 6.52 (5.91-7.12) 430 70,388 6.11 (5.53-6.69) 6.11 (5.53-6.69)
65-74 694 42,887 16.18 (14.98-17.39) 16.12 (14.92-17.32) 697 41,702 16.71 (15.47-17.95) 16.79 (15.54-18.03)
75-84 2,034 29,801 68.25 (65.29-71.22) 67.56 (64.62-70.50) 1,653 24,502 67.46 (64.21-70.72) 68.24 (64.95-71.53)
85+ 4,815 20,082 239.77 (232.99-246.54) 231.94 (225.39-238.49) 2,032 10,858 187.14 (179.01-195.28) 196.16 (187.63-204.69)
Total 8,099 236,881 34.19 (33.45-34.93) 28.92 (28.29-29.55) 4,913 225,143 21.82 (21.21-22.43) 26.53 (25.78-27.27)
Table 5 12-month prevalence of dementia among adults
45 years of age and older, Saskatchewan, by age group
(April 1, 2012 to March 31, 2013)
Age group n PAR Rate per 1,000 PAR (95 % CI)
45-54 211 153,400 1.38 (1.19-1.56)
55-64 876 138,792 6.31 (5.89-6.73)
65-74 1,391 84,589 16.44 (15.58-17.31)
75-84 3,687 54,303 67.90 (65.71-70.09)
85+ 6,847 30,940 221.30 (216.06-226.54)
Total 13,012 462,024 28.16 (27.68-28.65)
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focusing solely on incidence among those 65 years and
older in the present study, we find a similar rate of 19.1
per 1,000 PAR (3,023/157,907).
For the same 2012/13 period, the overall prevalence
rate of dementia among individuals aged 45 years and
older in the present study was 2.82 % (28.16 per 1,000
PAR). A previous Canadian registry study of dementia re-
ported a 12-month age-adjusted prevalence rate of 0.56 %
among non-First Nations vs. 0.75 % among First Nations
of all ages [43]. Other previous Canadian registry stud-
ies have reported 5-year prevalence rates ranging from
6.76 % among adults aged 66 and older [42] to rates
among adults aged 55 and older ranging from 10.6 %
[40] and 10.8 % [41] to 16.6 % [39].
In the present study, the 12-month prevalence rate was
3.9 times the 12-month incidence rate, indicating an
average duration of survival from time of identification of
3.9 years. Furthermore, females survived 0.64 years longer
on average than males, specifically 4.11 years vs. 3.47 years
from time of identification. In comparison, a recent report
by WHO and ADI [1] estimated worldwide annual de-
mentia prevalence to be greater than annual incidence by
a factor of 4.6, indicating that the average duration of sur-
vival, worldwide, was 4.6 years.
Incidence and prevalence by sex
Within age groups, significant sex differences in age-
standardised incidence rates of dementia were apparent
only in those 85 and older, with the standardised inci-
dence rate 10 % lower among females than males. Fur-
thermore, significant sex differences in age-standardised
prevalence rates were also apparent only in the 85 and
older age group, where the standardised prevalence rate
was 18 % higher among females than males. Overall, the
age-standardised incidence rate was significantly lower
among females than males aged 45 years and older by
8 % (7.04 vs. 7.65 per 1,000 PAR), however, the age-
standardised prevalence rate was significantly higher
among females than males by 9 % (28.92 vs. 26.53 per
1,000 PAR).
To the best of our knowledge, only one previous
Canadian registry study based on linked data (without
long-term care information), has examined dementia
prevalence by sex and age. For all ages 66 years and
older, Gill et al. [42] found the prevalence rate to be
23 % higher among females than males. Gill and col-
leagues [42] reported prevalence rates that were simi-
lar in females and males aged 66 to 74 years (2.7 %
and 2.6 %, respectively), but slightly higher in females
than males aged 75 to 84 years (9.1 % vs. 8.3 %) and
85 years and older (20.3 % vs. 18.3 %). Findings from
the Canadian Study of Health and Aging [53], a large
field study with community and institutionalized samples
combined, also reported prevalence rates that were higher
among females than males and that varied with age; the
overall prevalence rate among those aged 65 and older
was 25 % higher among females than males (86 vs. 69 per
1,000).
According to a WHO and ADI [1] systematic review
of 147 field studies published between 1980 and 2004,
the overall prevalence was 19 % to 29 % higher among
females than males aged 60 and older, with the excep-
tion of Asia Pacific and North America. Prince et al. [54]
concluded that a higher prevalence rate among females
than males, most notably among the oldest-old, suggests
that the average duration of survival is lengthier in fe-
males than males. Similarly, a US Alzheimer’s Association
report based mainly on field study data, concluded that a
greater prevalence of dementia among females than males
in the oldest age groups indicates that females are likely
to live longer with dementia than men [18]. The signifi-
cantly higher prevalence rate among females than males
aged 85 years and older in the current study would
seem to support these observations. Longer life expect-
ancy among females than males provides evidence for
these findings, with average life expectancy worldwide
slightly higher among females (72.7 years) than males
(68.1 years) [55].
Thies and Bleiler [18] suggest that negligible sex dif-
ferences in incidence across all age groups indicate
that females are no more likely than males to develop
dementia. The current study supports this observation
to a degree, as the age-standardised incidence rates did
not significantly differ by sex until age 85, at which point
Table 7 12-month age-standardised prevalence rates and female/male rate ratios among adults 45 years of age and older,
Saskatchewan, by gender and age group (April 1, 2012 to March 31, 2013)
Age group Female age-standardised rate per 1,000 PAR Male age-standardised rate per 1,000 PAR Rate ratio SD (RR) 95 % CI
45-54 1.45 1.30 1.12 0.138 0.851-1.461
55-64 6.52 6.11 1.07 0.068 0.935-1.218
65-74 16.12 16.79 0.96 0.054 0.864-1.067
75-84 67.56 68.24 0.99 0.033 0.928-1.056
85+ 231.94 196.16 1.18 0.027 1.123-1.245
Total 28.92 26.53 1.09 0.018 1.052-1.129
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Table 8 Incidence and prevalence of dementia among adults 45 years of age and older, by diagnosis code and other criteria at first
identification, Saskatchewan (April 1, 2012 to March 31, 2013)
Database and
diagnosis
code/other
criteria
Description of diagnosis code/other criteria Incident cases Prevalent cases
n Rate per 100
with incident
dementiaa
Rate per
10,000
PARb
n Rate per 100
with prevalent
dementiac
Rate per
10,000
PARd
Hospital Discharge Abstract Database (ICD-10-CA Codes)
F00.0 Dementia in Alzheimer’s Disease with early onset <6 * * 9 0.07 0.19
F00.1 Dementia in Alzheimer’s Disease with late onset <6 * * 16 0.12 0.35
F00.2 Dementia in Alzheimer’s Disease, atypical or mixed type <6 * * 19 0.15 0.41
F00.9 Dementia in Alzheimer’s Disease, unspecified 38 1.16 0.85 156 1.20 3.38
F01.0 Vascular dementia of acute onset <6 * * <6 * *
F01.1 Multifarct dementia 10 0.31 0.22 26 0.20 0.56
F01.2 Subcortical vascular dementia <6 * * 7 0.05 0.15
F01.3 Mixed cortical and subcortical vascular dementia <6 * * <6 * *
F01.8 Other vascular dementia <6 * * 14 0.11 0.30
F01.9 Vascular dementia, unspecified 47 1.44 1.05 189 1.45 4.09
F02.0 Dementia in Pick’s disease <6 * * 14 0.11 0.30
F02.1 Dementia in Creutzfeldt-Jakob disease <6 * * 0
F02.2 Dementia in Huntington’s disease 0 <6 * *
F02.3 Dementia in Parkinson’s disease 22 0.67 0.49 68 0.52 1.47
F02.4 Dementia in human immunodeficiency virus HIV disease 0 <6 * *
F02.8 Dementia in other specified diseases classified elsewhere <6 * * 16 0.12 0.35
F03 Unspecified dementia 611 18.69 13.61 1,737 13.35 37.60
F04 Organic amnesic syndrome, not induced by alcohol and other
psychoactive substances
0 <6 * *
F05.1 Delirium superimposed on dementia 54 1.65 1.20 158 1.21 3.42
F06.8 Other specified mental disorders due to brain damage
and dysfunction and to physical disease
0 15 0.12 0.32
F06.9 Unspecified mental disorder due to brain damage and
dysfunction and to physical disease
<6 * * 108 0.83 2.34
F09 Unspecified organic or symptomatic mental disorder <6 * * 14 0.11 0.30
F10.6 Mental and behavioural disorders due to use of alcohol,
amnesic syndrome
13 0.40 0.29 61 0.47 1.32
F10.7 Mental and behavioural disorders due to use of alcohol,
residual and late-onset psychotic disorder
8 0.24 0.18 59 0.45 1.28
F18.6 Mental and behavioural disorders due to use of volatile
solvents, amnesic syndrome
0 0 0.00 0.00
F18.7 Mental and behavioural disorders due to use of volatile
solvents, residual and late-onset psychotic disorder
0 0 0.00 0.00
F19.6 Mental and behavioural disorders due to multiple drug
use and use of other psychoactive substances, amnesic
syndrome
0 <6 * *
F19.7 Mental and behavioural disorders due to multiple drug
use and use of psychoactive substances, residual and
late-onset psychotic disorder
0 <6 * *
G30.0 Alzheimer’s disease with early onset 0 6 0.05 0.13
G30.1 Alzheimer’s disease with late onset <6 * * 10 0.08 0.22
G30.8 Other Alzheimer’s disease 0 18 0.14 0.39
G30.9 Alzheimer’s disease, unspecified 24 0.73 0.53 141 1.08 3.05
G31.0 Circumscribed brain atrophy 0 <6 * *
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the standardised rate was significantly lower among
females than males. This finding may be explained by
a lower likelihood of dementia in females than males
aged 85 and older, lower use of health care services
among females than males in this age group, or lower
identification of dementia among females than males
in this age category by health care professionals. Fur-
ther examination of these data is necessary to explore
sex differences in incidence rates across health care
settings.
Table 8 Incidence and prevalence of dementia among adults 45 years of age and older, by diagnosis code and other criteria at first
identification, Saskatchewan (April 1, 2012 to March 31, 2013) (Continued)
G31.1 Senile degeneration of brain, not elsewhere classified <6 * * 7 0.05 0.15
G91.0 Communicating hydrocephalus <6 * * <6 * *
G91.2 Normal-pressure hydrocephalus 8 0.24 0.18 49 0.38 1.06
R54 Senility 74 2.26 1.65 161 1.24 3.48
Total Hospital Discharge Abstract Database (ICD-10-CA Codes) 933 28.53 20.78 3,102 23.84 67.14
Physician Services Claims Database & Physician Characteristics Database (ICD-9 Codes)
290 Senile and presenile organic psychotic conditions 441 13.49 9.82 1,709 13.13 36.99
294 Other organic psychotic conditions chronic 23 0.70 0.51 107 0.82 2.32
331 Other cerebral degenerations 471 14.40 10.49 3,205 24.63 69.37
797 Senility without mention of psychosis 44 1.35 0.98 204 1.57 4.42
Total Physician Services Claims Database (ICD-9 codes) 979 29.94 21.80 5,225 40.16 113.09
Prescription Drug Database
Cholinesterase
Inhibitor
02232043,
02232044
Aricept 6+ * * 1,068 8.21 23.12
02242115-
02242118,
02245240
Exelon <6 * * 63 0.48 1.36
02244298-
02244300,
02266717,
02266725,
02266733
Reminyl <6 * * 337 2.59 7.29
Total Prescription Drug Database 214 6.54 4.77 1,468 11.28 31.77
Resident Assessment Index – Minimum Data Set (RAI-MDS)
CPS Scale
Scoree
2 Mild impairment (MMSE EA 19) 442 13.52 9.84 1118 8.59 24.20
3 Moderate impairment (MMSE EA 15) 441 13.49 9.82 1359 10.44 29.41
4 Moderately severe impairment (MMSE EA 7) 78 2.39 1.74 202 1.55 4.37
5 Severe impairment (MMSE EA 5) 110 3.36 2.45 355 2.73 7.68
6 Very severe impairment (MMSE EA 1) 35 1.07 0.78 91 0.70 1.97
Disease
category
mds_l1r Alzheimer’s Disease and CPS < 2 <6 * * 11 0.08 0.24
mds_l1v Dementia other than Alzheimer’s Disease and CPS < 2 6+ * * 81 0.62 1.75
Total Resident Assessment Index – Minimum Data Set (RAI-MDS) 1,144 34.98 25.48 3,217 24.72 69.63
TOTAL four databases 3,270 100.00 72.83 13,012 100.00 281.63
*Not reported due to an insufficient number of cases (i.e., between 1 and 5 cases) or an indeterminate number of cases
aIncident number of case defined dementia (N = 3,270)
bPopulation at risk for incident dementia (N = 449,012)
cPrevalent number of case defined dementia (N = 13,012)
dPopulation at risk for prevalent dementia (N = 462,024)
eMini-Mental State Examination Equivalent Average (MMSE EA) scores derived from Morris et al. 1994 [50]
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Incidence and prevalence by age group
In the present study, the incidence rate escalated by 2.8
to 5.1 times every 10 years, increasing 152-fold between
adults aged 45 to 54 and those aged 85 years and older
(0.46 vs. 69.73 per 1,000 PAR). Further, the incidence
rate was 17.7 times higher among adults 85 years and
older than 65 to 74 years (69.73 vs. 3.95 per 1,000 PAR).
These findings are consistent with other studies. The
CSHA study [20] reported that incidence doubled every
five years, with incidence 19.4 times higher among
adults 85 years and older than 65 to 70 years (106.5 vs.
5.5 per 1,000). According to a WHO and ADI [1] sys-
tematic review of field studies, incidence among adults
60 years and older doubled every 5.9 years, from 3.1 per
1,000 person years among adults 60 to 64 years to 175.0
per 1,000 person years after age 95 years. In the present
study, incidence peaked at 6.97 % (69.73 per 1,000 PAR)
after age 85 years. Similarly, the WHO and ADI report
[1] found that North American dementia incidence
peaked between ages 80 and 89.
The 12-month prevalence rate in the present study
increased by between 2.6 and 4.6 times every 10 years
after age 45 years. Overall, the prevalence rate increased
13.5 times between ages 65 to 74 and 85 and older (16.4
vs. 221.3 per 1,000 PAR), and grew 160-fold between
ages 45 to 54 and 85 years and older (1.38 to 221.3 per
1,000 PAR). The single comparable Canadian registry
study that examined dementia prevalence by age found
an increase of 7.3 times between the age groups 65 to 74
and 85 and older [42]. The findings of the present
study are consistent with the CSHA [20] findings that
prevalence increased 14.4 times between the age groups
65 to 74 and 85 and older (24 vs. 345 per 1,000). Further,
a WHO and ADI [1] systematic review concluded that
dementia prevalence doubled with every 5.5 years of age.
A recent review of field and registry studies of early
onset dementia (before aged 65 years), conducted in
European countries, USA, and Japan, found prevalence
rates ranging from 0.38 to 4.2 per 1,000 among indi-
viduals ages 20 to 64 years [56]. The prevalence rates
among individuals aged 45 to 54 years and 55 to 64 years
in the present study are higher in comparison at 1.38
and 6.11 per 1,000 PAR, respectively. This difference
may be due partly to the higher age cutoff in the present
study at 45 years, compared with a lower age cutoff of
20 years in the review. Although early onset dementia is
less common than dementia in adults over aged 65 years,
it is important to consider the different nature of the
impact of dementia on these individuals and their fam-
ilies, who are more likely to be employed in the work-
force, under greater financial pressures, with younger
families and perhaps frail parents [21].
Incidence and prevalence by diagnosis code and other
criteria
In the present study, incident cases were first identified
more often in long-term care (34.98 %) than other set-
tings (29.94 % physician services claims; 28.53 % hos-
pital; 6.54 % cholinesterase inhibitor prescription). Of all
incident cases, 27.89 % were first identified at the point
of admission to long-term care. These findings indicate
that approximately one in four individuals with incident
Table 9 Timing of identification of incident and prevalent dementia in Long-term Care among adults 45 years of age and older,
Saskatchewan, by criteria at first identification (April 1, 2012 to March 31, 2013)
Criteria at first identification of dementia Incident cases (N = 1,144) Prevalent cases (N = 3,217)
First identification
at admissiona
First identification ≥30 days
after admissionb
First identification
at admissionb
First identification ≥30 days
after admissionb
n % n % n % n %
CPS Scale Scorec
2 Mild impairment (MMSE EA 19) 334 75.56 108 24.44 769 68.78 349 31.22
3 Moderate impairment (MMSE EA 15) 358 81.17 83 18.83 945 69.53 414 30.46
4 Moderately severe impairment (MMSE EA 7) 70 89.74 8 10.26 145 71.78 57 28.22
5 Severe impairment (MMSE EA 5) 95 86.36 15 13.64 241 67.89 114 32.11
6 Very severe impairment (MMSE EA 1) 28 80.0 7 20.0 52 57.14 39 42.85
Disease category
Alzheimer disease and CPS <2 <6 * <6 * 6+ * <6 *
Dementia other than Alzheimer disease and CPS <2 6+ * 6+ * 6+ * 6+ *
Total 912 79.72 232 20.28 2,216 68.89 1,001 31.11
*Not reported due to an insufficient number of cases (i.e., between 1 and 5) or an indeterminate number of cases
aAdmission occurred April 1, 2012 to March 31, 2013
bAdmission occurred prior to April 1, 2012
cMini-Mental State Examination Equivalent Average (MMSE EA) scores derived from Morris et al. 1994 [50]
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dementia were admitted to long-term care before a for-
mal diagnosis of dementia was recorded in physician or
hospital data. These findings also underscore the issue of
underdiagnosis, attributable to many factors internal and
external to the health system [10, 11, 14].
Prevalent cases in the present study were more likely to
be first identified in physician services claims (40.16 %)
than other settings (24.72 long-term care; 23.84 % hos-
pital; 11.28 % cholinesterase inhibitor prescription). Diag-
noses in physician data were non-specific as a function of
the four ICD-9 codes available (290, 294, 331, and 797);
24.63 % of all prevalent cases were first identified with a
formal diagnosis of ‘other cerebral degenerations’ and
13.13 % with a diagnosis of ‘senile and presenile organic
psychotic conditions’. A further 13.35 % of all prevalent
cases were first identified with a diagnosis of ‘unspecified
dementia’ in hospital data. Given the large number of
diagnosis codes available in hospital (25 vs. one code in
physician data), this finding suggests that the tendency
among physicians to choose non-specific diagnosis codes
regardless of the number of codes available may reflect
diagnostic uncertainty or a large proportion of mixed
pathologies. Alzheimer disease (AD) is the most common
type of dementia, and mixed pathologies in dementia are
far more common than pure pathologies [1]. A study of
1,050 autopsy dementia cases found that the large ma-
jority (62.9 %) were likely Alzheimer Disease, and a
minority were non-AD, specifically 10.4 % were non-
specific degenerative dementia, 10.0 % vascular demen-
tia, 9.5 % Parkinson disease with dementia, and 1.5 %
mixed dementia [57]. Further, fewer than half (43 %)
were likely pure Alzheimer’s disease.
Limitations
This study may have resulted in either an over- or an
under-estimation of incidence and prevalence rates.
First, given that dementia is significantly underdiagnosed
in the health care system, studies based on administra-
tive data tend to underestimate the number of individ-
uals with dementia, particularly among older age groups
[56]. In comparison, field studies tend to have greater
sensitivity for identifying cases and therefore generally
report higher rates than registry studies [56]. In the
present study, underestimation also may have resulted
from not including home care data in our analysis (as it
was not available). Furthermore, physician services claims
allow a maximum of one diagnosis code per claim, which
may hinder physicians from recording a dementia-related
diagnosis for patients with co-morbid conditions or con-
ditions that are less challenging to diagnose and may
in turn result in underestimation in physician data. In
addition, reluctance among individuals to seek help from
health care professionals for issues related to cognitive
function contributes to the likelihood that physician data
underestimate the true incidence and prevalence of de-
mentia. Second, overestimation of incidence and preva-
lence rates may have occurred as a result of several
factors. For instance, the case definition algorithm devel-
oped for this study required only one diagnosis or other
criterion of dementia. However, this algorithm is compar-
able to other Canadian studies of dementia epidemiology
that also employed a minimum of one diagnosis in phys-
ician or hospital data. It is also possible that individuals
who were not identified in physician data (perhaps due
to the fact that one diagnosis code per claim is allowed)
were later identified with dementia in the hospital dis-
charge abstract database which permits up to 25 diagnoses
per record, resulting in overestimation in hospital data.
Overestimation may also have resulted from identifying
individuals with incident dementia when they had fewer
than five years of uninterrupted health insurance prior to
their index date (i.e., gaps of no more than 3 consecutive
days). Lastly, the Cognitive Performance Scale (CPS) score
used in our algorithm, derived from the provincial RAI-
MDS (long-term care) database, focuses primarily on cog-
nitive function and therefore may overestimate incidence
and prevalence of dementia (since a diagnosis requires
both functional and cognitive impairment).
Conclusions
In the present study, we linked together 10 provincial-
level databases, including four administrative health
databases (physician, hospital, prescription drug, and long-
term care), to determine the incidence and prevalence of
dementia among adults aged 45 years and older across
multiple settings. This study found that for every 10 years
of age after age 45 years, the incidence rate increased by 2.8
to 5.1 times and the prevalence rate increased by 2.6 to 4.6
times. The findings indicated an average duration of sur-
vival from time of diagnosis of 3.9 years, with females sur-
viving an average of 0.64 years longer than males. After age
standardisation, the incidence rate was significantly lower
but the prevalence rate was significantly higher overall
among females than males, due largely to significant sex
differences in the oldest age group. Among females com-
pared to males aged 85 and older, the lower incidence rate
but higher prevalence rate of dementia suggest a lower
likelihood of dementia or perhaps lower formal recognition,
but longer disease duration, among females than males in
this age group.
We also found that approximately one-quarter of all
incident cases were admitted to long-term care before a
diagnosis was formally recorded in physician or hospital
data, and 63.38 % (578/912) of these cases were identi-
fied at admission with impairment at the moderate to
very severe level (CPS Scale Score ≥ 3) or a disease
category of Alzheimer’s disease/other dementia. We sug-
gest that the maximum limit of one diagnosis code per
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service claim hinders physicians from formally recording
a diagnosis for a greater number of individuals with
dementia, and therefore recommend that the number of
diagnosis codes allowed per physician services claim be
increased. Linking multiple sources of registry data con-
tributes to our understanding of the epidemiology of
dementia across multiple segments of the population,
inclusive of individuals residing in long-term care. Fu-
ture research that employs linked administrative would
ideally incorporate Home Care data to determine whether
this dataset contains additional cases of dementia.
Additional file
Additional file 1: Diagnosis codes and other criteria employed to
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